Rare Biomarkers Specimen Collection And Stabilization Market on Track for Strong Growth, Estimated to Grow at 10.3% CAGR Through 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Rare Biomarkers Specimen Collection And Stabilization Market Through 2025?
The market size for the collection and stabilization of rare biomarkers specimens has experienced fast-paced growth in recent years. It's expected to expand from $32.01 billion in 2024 to $35.4 billion in 2025, with a compound annual growth rate (CAGR) of 10.6%. The previous growth can be credited to factors such as the human genome project, a rise in cancer research, the investment in pharmaceutical R&D, the development of genomics and proteomics field, along with advancements in data management and bioinformatics.

What's the Projected Size of the Global Rare Biomarkers Specimen Collection And Stabilization Market by 2029?
The market size of the rare biomarkers specimen collection and stabilization sector is projected to witness a notable expansion in the upcoming years, reaching a value of $52.46 billion in 2029, with a compound annual growth rate (CAGR) of 10.3%. This growth during the predicted period is anticipated to be driven by factors such as the development of liquid biopsy applications, heightened consumer awareness and demand, the increasing preference for non-invasive procedures, and the discovery of biomarkers in seldom seen diseases. Key trends predicted to emerge throughout the forecast period include improvements in preservation technology, advances in genomic and proteomic investigation, the rise of point-of-care testing, regulatory improvements and standardization, ameliorated data analytics, and the integration of Artificial Intelligence.

View the full report here:
https://www.thebusinessresearchcompany.com/report/rare-biomarkers-specimen-collection-and-stabilization-global-market-report

Top Growth Drivers in the Rare Biomarkers Specimen Collection And Stabilization Industry: What's Accelerating the Market?
The growth of the rare biomarker specimen collection and stabilization market is anticipated to be boosted by the escalating occurrence of cancer. Characterized by unchecked growth and spread of abnormal cells, cancer is a multitude of diseases. Environmental pollutants and lifestyle choices such as smoking and poor diet, aggravating genetic risks, are causing a surge in cancer prevalence. The employment of rare biomarker specimen collection and stabilization techniques in cancer prevalence research allows for more precise identification and tracking of particular cancer types, improving diagnosis and treatment methods. For example, a report from the European Commission, a governing body based in Europe, in October 2023 showed that new cancer cases have gone up to 2.74 million in 2022, reflecting a 2.3% rise from 2020. Consequently, the rising occurrence of cancer is fueling the expansion of the rare biomarker specimen collection and stabilization market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15913&type=smp

What Trends Will Shape the Rare Biomarkers Specimen Collection And Stabilization Market Through 2029 and Beyond?
Mainstream businesses in the niche sector of rare biomarker specimen collection and stabilization are concentrating on the creation of novel solutions, including a pre-analytical platform for automating plasma and cell sample preparations for multiomic liquid biopsy. This platform offers consistent, automated preparation of fresh samples during blood collection and removes the need for special tubes or highly trained professionals, thereby preserving the integrity of the sample. For example, Tethis S.p.A., a biotech enterprise based in Italy, introduced See.d in May 2022. This is the first fully automated, standardized pre-analytical platform with unique capabilities like accurate sample handling, effective plasma separation for cellular fractions, and immobilization of white blood cells on SmartBioSurface slides. The platform comes with a quality control score system to objectively assess sample stability. This methodology facilitates the systematic evaluation of proteomics and metabolomics data sets to establish the stability of plasma and serum samples.

What Are the Main Segments in the Rare Biomarkers Specimen Collection And Stabilization Market?
The rare biomarkers specimen collection and stabilization market covered in this report is segmented -

1) By Type: Circulating Cell Free Deoxyribonucleic Acid (CCFDNA), Circulating Tumor Cells (CTCs), Exosomes or Extracellular Vesicles
2) By Specimen: Serum Or Plasma, Other Specimens
3) By Application: Non-Invasive Prenatal Testing (NIPT), Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, Other Applications
4) By End-User: Hospitals, Perinatal Clinics, Public Health Labs, Private Or Commercial Labs, Physician Labs, Research Institutes, Other End-Users

Subsegments:
1) By Circulating Cell Free Deoxyribonucleic Acid (CCFDNA): Plasma CCFDNA, Serum CCFDNA
2) By Circulating Tumor Cells (CTCs): CTCs In Blood, CTCs In Bone Marrow
3) By Exosomes Or Extracellular Vesicles: Exosomes From Plasma, Exosomes From Serum

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15913&type=smp

Which Top Companies are Driving Growth in the Rare Biomarkers Specimen Collection And Stabilization Market?
Major companies operating in the rare biomarkers specimen collection and stabilization market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Miltenyi Biotec GmbH, Natera Inc., Promega Corporation, Myriad Genetics, Hamilton Company, OraSure Technologies Inc., Fluidigm Corporation, Streck Inc., SeraCare, Enzo Biochem Inc., Epigenomics AG, Veridex LLC

Which Regions Will Dominate the Rare Biomarkers Specimen Collection And Stabilization Market Through 2029?
North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare biomarkers specimen collection and stabilization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15913

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.